Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
The present invention relates to a DNA construct encoding one or more human IGF-1 isoforms that can be used for treatment of neuropathy. Further provided herein are a pharmaceutical composition including the DNA construct as an active ingredient and a method of administering the DNA construct for treatment of neuropathy. The present invention provides a safe and effective way of treating neuropathic patients.
1. An IGF-1 encoding DNA construct, comprising:
a first polynucleotide that has the sequence of (SEQ ID NO: 1) or a degenerate thereof;
a second polynucleotide that has the sequence of SEQ ID NO: 6 or SEQ ID NO: 7;
a third polynucleotide that has the sequence of (SEQ ID NO: 3) or a degenerate thereof;
a fourth polynucleotide that has the sequence of (SEQ ID NO: 4) or a fragment thereof; and
a fifth polynucleotide that has the sequence of (SEQ ID NO: 5) or a degenerate thereof,
wherein the first polynucleotide, the second polynucleotide, the third polynucleotide, the fourth polynucleotide and the fifth polynucleotide are linked in sequential 5′ to 3′ order.
2. The IGF-1 encoding DNA construct of claim 1 , wherein the fourth polynucleotide is a polynucleotide of SEQ ID NO: 8.
3. The IGF-1 encoding DNA construct of claim 1 , further comprising a plasmid vector.
4. The IGF-1 encoding DNA construct of claim 3 , wherein the plasmid vector is pCK.
5. The IGF-1 encoding DNA construct of claim 4 , wherein the construct is pCK-IGF-1X6 or pCK-IGF-1X10.
6. The IGF-1 encoding DNA construct of claim 3 , wherein the plasmid vector is pTx.
7. The IGF-1 encoding DNA construct of claim 6 , wherein the construct is pTx-IGF-1X10.
8. The IGF-1 encoding DNA construct of claim 6 , wherein the construct is pTx plasmid containing IGF-1X6 having the sequence of SEQ ID NO: 9.
9. A pharmaceutical composition comprising the IGF-encoding DNA construct of claim 8 .
10. A pharmaceutical composition comprising the IGF-1 encoding DNA construct of claim 1 .
11. The pharmaceutical composition of claim 10 , wherein the IGF-1 encoding DNA construct is pCK-IGF-1X6, pCK-IGF-1X10 or pTx-IGF-1X10.
12. An IGF-1 encoding DNA construct, comprising:
a first polynucleotide that has the sequence of SEQ ID NO: 1 or a degenerate thereof;
a second polynucleotide that has the sequence of SEQ ID NO: 2 or a fragment thereof;
a third polynucleotide that has the sequence of SEQ ID NO: 3 or a degenerate thereof;
a fourth polynucleotide that has the sequence of SEQ ID NO: 8; and
a fifth polynucleotide that has the sequence of SEQ ID NO: 5 or a degenerate thereof,
wherein the first polynucleotide, the second polynucleotide, the third polynucleotide, the fourth polynucleotide and the fifth polynucleotide are linked in sequential 5′ to 3′ order.
13. The IGF-1 encoding DNA construct of claim 12 , wherein the second polynucleotide has the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.
14. The IGF-1 encoding DNA construct of claim 12 , further comprising a plasmid vector.
15. A pharmaceutical composition comprising the IGF-1 encoding DNA construct of claim 12 .